Change in Preferred Drug List (PDL) Status for Generic Sildenafil Oral Suspension

Date: September 30, 2024
Attention: Providers
Effective date: September 25, 2024

Call to action: Effective September 25, 2024, the Texas Health and Human Services (HHS) removed non-preferred status from generic sildenafil oral suspension This is in response to the discontinuation of brand Revatio suspension by the manufacturer.

The preferred status of the brand name Revatio oral suspension will not change to allow any current stock to be used.

Next step for Providers: Prescribers are encouraged to proactively obtain a prescription for the preferred alternatives to avoid disruption in patient’s therapy. Prescribers should share this communication with their staff.

Please see below for the list of impacted drugs (of note, the approval is NDC-specific):

Preferred Medication NDC	Preferred Medication	Type of Change	Effective Date
00591405094	SILDENAFIL 10 MG/ML ORAL SUSP	Generic now preferred	September 25, 2024
27241017529	SILDENAFIL 10 MG/ML ORAL SUSP	Generic now preferred	September 25, 2024
31722013631	SILDENAFIL 10 MG/ML ORAL SUSP	Generic now preferred	September 25, 2024
59762205801	SILDENAFIL 10 MG/ML ORAL SUSP	Generic now preferred	September 25, 2024
68180028301	SILDENAFIL 10 MG/ML ORAL SUSP	Generic now preferred	September 25, 2024
69238157401	SILDENAFIL 10 MG/ML ORAL SUSP	Generic now preferred	September 25, 2024
70710171604	SILDENAFIL 10 MG/ML ORAL SUSP	Generic now preferred	September 25, 2024
70954016810	SILDENAFIL 10 MG/ML ORAL SUSP	Generic now preferred	September 25, 2024
72205005976	SILDENAFIL 10 MG/ML ORAL SUSP	Generic now preferred	September 25, 2024

If you have any questions, please email TCHP Pharmacy at: tchppharmacy@texaschildrens.org.

For access to all provider alerts,log into:
www.thecheckup.org or www.texaschildrenshealthplan.org/for-providers.